AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.